Insider · CIK 0001444717

AISLING CAPITAL III LP

Reports to the SEC for 8 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001444717

Forms 4 and 5

Insider transactions

43 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2018-07-10	Loxo Oncology, Inc.S Sale	10% Owner	SSale	−1.4M sh	$179.43	−$251M	2,038,920
2017-12-19	Loxo Oncology, Inc.S Sale	10% Owner	SSale	−250K sh	$80.50	−$20.1M	3,438,920
2017-11-22	Loxo Oncology, Inc.S Sale	10% Owner	SSale	−500K sh	$75.00	−$37.5M	3,688,920
2017-01-10	Loxo Oncology, Inc.P Purchase	10% Owner	PPurchase	+160K sh	$31.00	+$4.96M	4,188,920
2016-07-06	Syros Pharmaceuticals, Inc.C Conversion	10% Owner	CConversion	+509K sh	—	—	508,565
2016-07-06	Syros Pharmaceuticals, Inc.Series B Preferred StockC Conversion	10% Owner	CConversion	−1.91M sh	—	—	0
2016-07-06	Syros Pharmaceuticals, Inc.P Purchase	10% Owner	PPurchase	+400K sh	$12.50	+$5M	908,565
2016-06-02	AGILE THERAPEUTICS INCJ Other	10% Owner	JOther	−400K sh	—	—	2,583,797
2016-05-17	Loxo Oncology, Inc.P Purchase	10% Owner	PPurchase	+233K sh	$21.50	+$5M	4,028,920
2015-12-11	Loxo Oncology, Inc.P Purchase	10% Owner	PPurchase	+200 sh	$27.50	+$5,500	3,796,362
2015-12-09	T2 Biosystems, Inc.P Purchase	10% Owner	PPurchase	+308K sh	$9.75	+$3M	2,830,992
2015-11-17	Loxo Oncology, Inc.P Purchase	10% Owner	PPurchase	+265K sh	$26.50	+$7.02M	3,796,182
2015-11-13	Loxo Oncology, Inc.P Purchase	10% Owner	PPurchase	+1,955 sh	$27.47	+$53.7K	3,531,182
2015-11-12	Loxo Oncology, Inc.P Purchase	10% Owner	PPurchase	+76.7K sh	$27.65	+$2.12M	3,529,207
2015-01-27	Aravive, Inc.P Purchase	10% Owner	PPurchase	+145K sh	$17.25	+$2.5M	2,139,568
2015-01-23	AGILE THERAPEUTICS INCP Purchase	10% Owner	PPurchase	+812K sh	$5.85	+$4.75M	2,983,797
2014-08-12	T2 Biosystems, Inc.Series E Convertible Preferred StockC Conversion	10% Owner	CConversion	−550K sh	—	—	0
2014-08-12	T2 Biosystems, Inc.C Conversion	10% Owner	CConversion	+2.07M sh	—	—	2,068,755
2014-08-12	T2 Biosystems, Inc.P Purchase	10% Owner	PPurchase	+455K sh	$11.00	+$5M	2,523,300
2014-08-12	T2 Biosystems, Inc.Series D Convertible Preferred StockC Conversion	10% Owner	CConversion	−2.97M sh	—	—	0
2014-08-06	Loxo Oncology, Inc.P Purchase	10% Owner	PPurchase	+413K sh	$13.00	+$5.37M	3,452,493
2014-08-06	Loxo Oncology, Inc.Series A Convertible Preferred StockC Conversion	10% Owner	CConversion	−2.34M sh	—	—	0
2014-08-06	Loxo Oncology, Inc.Series B Convertible Preferred StockC Conversion	10% Owner	CConversion	−507K sh	—	—	0
2014-08-06	Loxo Oncology, Inc.C Conversion	10% Owner	CConversion	+2.85M sh	—	—	3,039,416
2014-03-26	Aravive, Inc.Series C Convertible Preferred StockC Conversion	10% Owner	CConversion	−14.2M sh	—	—	0
2014-03-26	Aravive, Inc.Series D-2 Convertible Preferred StockC Conversion	10% Owner	CConversion	−655K sh	—	—	0
2014-03-26	Aravive, Inc.Series E Convertible Preferred StockC Conversion	10% Owner	CConversion	−5.49M sh	—	—	0
2014-03-26	Aravive, Inc.C Conversion	10% Owner	CConversion	+129K sh	—	—	1,400,514
2014-03-26	Aravive, Inc.C Conversion	10% Owner	CConversion	+1.24M sh	—	—	1,271,819
2014-03-26	Aravive, Inc.C Conversion	10% Owner	CConversion	+35.1K sh	—	—	35,104
2014-03-26	Aravive, Inc.C Conversion	10% Owner	CConversion	+477K sh	—	—	1,934,568
2014-03-26	Aravive, Inc.C Conversion	10% Owner	CConversion	+56.9K sh	—	—	1,457,453
2014-03-26	Aravive, Inc.P Purchase	10% Owner	PPurchase	+60K sh	$21.00	+$1.26M	1,994,568
2014-03-26	Aravive, Inc.Series B Convertible Preferred StockC Conversion	10% Owner	CConversion	−404K sh	—	—	0
2014-03-26	Aravive, Inc.Series D-1 Convertible Preferred StockC Conversion	10% Owner	CConversion	−1.48M sh	—	—	0
2014-03-21	Durata Therapeutics, Inc.S Sale	10% Owner	SSale	−2,649 sh	$15.57	−$41.3K	3,030,175
2014-03-20	Durata Therapeutics, Inc.S Sale	10% Owner	SSale	−98K sh	$15.74	−$1.54M	3,032,824
2013-12-06	ASENSUS SURGICAL, INC.C Conversion	Former 10% Owner	CConversion	+12.4M sh	—	—	36,490,260
2013-09-03	ASENSUS SURGICAL, INC.Series B Preferred StockP Purchase	Former 10% Owner	PPurchase	+1.24M sh	$4.00	+$4.96M	1,240,176.4
2012-07-24	ASENSUS SURGICAL, INC.Series B Preferred StockC Conversion	Former 10% Owner	CConversion	−1.24M sh	—	—	0
2012-07-24	Durata Therapeutics, Inc.C Conversion	10% Owner	CConversion	+2.02M sh	—	—	2,019,713
2012-07-24	Durata Therapeutics, Inc.P Purchase	10% Owner	PPurchase	+1.11M sh	$9.00	+$10M	3,130,824
2012-07-24	Durata Therapeutics, Inc.Series A Preferred StockC Conversion	10% Owner	CConversion	−16.2M sh	—	—	0

Recent filings

Accepted (ET)
Jul 124
AISLING CAPITAL III LP0000899243-18-019810
SEC(opens sec.gov)
Dec 204
ELMS STEVE0000950142-17-002235
SEC(opens sec.gov)
Nov 274
ELMS STEVE0000950142-17-002107
SEC(opens sec.gov)
Jan 124
Loxo Oncology, Inc.0000950142-17-000108
SEC(opens sec.gov)
Jul 64
Syros Pharmaceuticals, Inc.0000950142-16-004060
SEC(opens sec.gov)
Jun 34
AGILE THERAPEUTICS INC0000950142-16-003866
SEC(opens sec.gov)
May 194
Loxo Oncology, Inc.0000950142-16-003763
SEC(opens sec.gov)
Dec 154
Loxo Oncology, Inc.0000950142-15-002621
SEC(opens sec.gov)
Dec 94
T2 Biosystems, Inc.0000950142-15-002576
SEC(opens sec.gov)
Nov 194
Loxo Oncology, Inc.0000950142-15-002461
SEC(opens sec.gov)
Nov 164
Loxo Oncology, Inc.0000950142-15-002434
SEC(opens sec.gov)
Jan 294
Versartis, Inc.0000950142-15-000194
SEC(opens sec.gov)
Jan 274
AGILE THERAPEUTICS INC0000950142-15-000157
SEC(opens sec.gov)
Aug 144
T2 Biosystems, Inc.0001104659-14-061090
SEC(opens sec.gov)

Companies

Address

888 SEVENTH AVENUE THIRTIETH FLOOR

NEW YORK, NY, 10106